OR641 / OncoResponse - LARVOL DELTA

ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments (Businesswire) - "ImmunoPrecise Antibodie...today proudly announces the clinical progress achieved with rabbit monoclonal antibodies designed and developed using IPA’s proprietary B Cell Select platform for the clinical-stage company, OncoResponse Inc...In a live presentation at the recent PEGS 2024 conference, OncoResponse shared exciting updates on two novel antibodies, OR502 and OR641...OR502, a novel, humanized anti-leukocyte immunoglobulin like receptor B2 (LILRB2) antibody, has successfully entered Phase I/II clinical trials, showing excellent safety profile, and is being evaluated for efficacy in treating advanced solid tumors....OR641, a novel, humanized dual antagonist antibody targeting both LILRB1 and LILRB2, has completed Cell Line Development and is undergoing IND-enabling studies. Preclinical models have demonstrated its superior ability to reverse immunosuppression caused by myeloid and lymphoid cells compared to other anti-LILRB1/2 antibodies."

Preclinical • Trial status • Oncology • Solid Tumor

OR641 is a novel dual antagonist antibody that targets LILRB1 and LILRB2 inhibitory receptors and promotes a Th1-like immune response (SITC 2023) - "OR641 modulates immunosuppressive myeloid cells through blockade of LILRB1 and LILRB2 and stimulates both innate and adaptive immune responses. These data provide a strong rationale for further development of OR641 as a treatment for solid tumor malignancies."

Oncology • Solid Tumor • IFNG • IL10 • LILRB1 • LILRB2

OncoResponse Presents at AACR 2023 Annual Meeting Preclinical Data Highlighting Dual Antagonist Antibodies Targeting both LILRB1 and LILRB2 (PRNewswire) - "OncoResponse...presented preclinical data highlighting its identification of dual antagonist antibodies targeting both LILRB1 and LILRB2 as potential anti-cancer immunotherapies at the American Association for Cancer Research Annual Meeting....The presentation highlighted the discovery and characterization of dual antagonist antibodies that target both LILRB1 and LILRB2, inhibitory receptors that promote immunosuppression within the tumor microenvironment. Data presented demonstrate:...Enhanced NK cell-mediated cytotoxicity; Robust anti-tumor activity in an SK-MEL-5 tumor model in humanized NSG-SGM3 mice."

Preclinical • Oncology